Ulrich Herrlinger

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.

Martin Glas, Michael Weller, Johannes Rieger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma

Martin Glas, Elke Hattingen, Rolf Fimmers, 2016, Oncotarget.

Glioblastoma multiforme from diagnosis to death: a prospective, hospital-based, cohort, pilot feasibility study of patient reported symptoms and needs

Martin Hellmich, Michael Schroeter, Raymond Voltz, 2014, Supportive Care in Cancer.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Martin Glas, Michael Sabel, Jörg-Christian Tonn, 2019, The Lancet.

Vessel Wall Contrast Enhancement: A Diagnostic Sign of Cerebral Vasculitis

Peter M. Rothwell, Wilhelm Küker, Jens Fiehler, 2008, Cerebrovascular Diseases.

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET

Gereon R. Fink, Karl-Josef Langen, Martin Kocher, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov

Claus Belka, Maximilian Niyazi, Evelyn Herrmann, 2017, Radiation Oncology.